Vimta Labs Limited has informed the Exchange regarding a press release dated November 03, 2025, titled "Q2- FY 2025-26- Unaudited Financial Results for the Quarter and Half Year ended 30.09.2025.".
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vimta Labs reported its highest-ever quarterly revenue of Rs. 1,045 Mn in Q2 FY26, up 22.3% year-on-year and 5.2% quarter-on-quarter. EBITDA grew 20.6% YoY to Rs. 369 Mn with margins of 35.3%, while profit after tax rose 17.1% YoY to Rs. 199 Mn, translating to a basic EPS of Rs. 4.5. For H1 FY26, total income stood at Rs. 2,038 Mn (up 26.6% YoY) with PAT of Rs. 388 Mn (up 25.6% YoY) and EPS of Rs. 8.7. Growth was driven by strong performance in pharmaceutical research/testing and food testing services. The company also successfully cleared a WHO audit for Clinical Research during the quarter.
Strong quarterly results with record revenue, healthy margin profile (~35% EBITDA, ~19% PAT), and double-digit profit growth signal continued business momentum and are likely to be viewed positively by investors. The post-divestiture focus on core contract research appears to be delivering consistent growth.